Since tucatinib was recently introduced for treatment of HER2+ breast cancers [13], and Bcl-2 is suggested to play a role in this form of cancer [14, 15], we wanted to test tucatinib and venetoclax in vivo. Here, ERBB2 is linked to breast carcinoma.